<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929744</url>
  </required_header>
  <id_info>
    <org_study_id>17416</org_study_id>
    <secondary_id>J2A-MC-GZGA</secondary_id>
    <nct_id>NCT03929744</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Healthy Participants</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purposes of this study are to determine:

        -  The safety of LY3502970 and any side effects that might be associated with it.

        -  How much LY3502970 gets into the bloodstream and how long it takes the body to get rid
           of it.

      This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970
      and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last
      about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days.
      Each participant will enroll in only one part. Screening must be completed within 28 days
      before study start. This study is for research purposes only, and is not intended to treat
      any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">December 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part C is a crossover design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline up to Day 42</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970</measure>
    <time_frame>Predose up to 96 hours postdose</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970</measure>
    <time_frame>Predose up to 96 hours postdose</time_frame>
    <description>PK: AUC(0-tlast) of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time of Maximum Observed Concentration (Tmax) of LY3502970</measure>
    <time_frame>Predose up to 96 hours postdose</time_frame>
    <description>PK: Tmax of LY3502970</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3502970 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 (Part C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3502970 administered orally in each of two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 (Part D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Formulation 1 (Part E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 - formulation 1 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Formulation 2 (Part E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 - formulation 2 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970 (Part A)</arm_group_label>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_label>LY3502970 (Part C)</arm_group_label>
    <arm_group_label>LY3502970 (Part D)</arm_group_label>
    <arm_group_label>LY3502970 Formulation 1 (Part E)</arm_group_label>
    <arm_group_label>LY3502970 Formulation 2 (Part E)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_label>Placebo (Part D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or females, as determined by medical history

          -  Have safety laboratory results within normal reference ranges

        Exclusion Criteria:

          -  Have known allergies to LY3502970, glucagon-like peptide-1 (GLP-1) analogs, related
             compounds

          -  Abnormal electrocardiogram (ECG) at screening

          -  Significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological or neurological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-647-9300</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

